Skip left side navigation and go to content
NHLBAC Meeting Minutes - February 15, 2012
The 245th meeting of the National Heart, Lung, and Blood Advisory Council (NHLBAC) was convened on Thursday, February 15, 2012, in Conference Room 10, C Wing, Building 31, National Institutes of Health (NIH), Bethesda, Maryland. The meeting was open to the public from 8:30 a.m. to 11:45 a.m. The meeting was closed to the public from 12:35 p.m. to adjournment at 2:15 p.m. Dr. Susan B. Shurin, Acting Director of the National Heart, Lung, and Blood Institute (NHLBI), presided as Chair.
COUNCIL MEMBERS PRESENT:
Ms. Coletta C. Barrett
COUNCIL MEMBERS ABSENT:
Mr. Jonathan R. Alger
Dr. Talmadge E. King, Jr.
Dr. Arun Chockalingam
MEMBERS OF THE PUBLIC PRESENT:
Dr. Diane Catellier, RTI International
NIH EMPLOYEES PRESENT:
Mr. Brian Thompson,
CSR EMPLOYEES PRESENT:
Dr. George Barnas
NHLBI EMPLOYEES PRESENT:
Numerous NHLBI staff members were in attendance or were able to view the meeting via closed circuit broadcast.
Dr. Susan B. Shurin, Acting Director of the National Heart, Lung, and Blood Institute (NHLBI), welcomed members to the 245th meeting of the National Heart, Lung, and Blood Advisory Council (NHLBAC).
Dr. Shurin welcomed three new Council members:
Dr. Shurin updated the Council on NHLBI leadership appointments:
Dr. Kathy Hudson, Deputy Director for Science, Outreach, and Policy at the NIH, and Acting Deputy Director of the National Center for Advancing Translational Sciences updated the Council on revising the Common Rule on human subjects protections. The Common Rule was adopted by many federal agencies in 1991, but since then, the human subjects research landscape has changed, and human subjects regulations have not kept up with the changes.
The regulations are being revised, and an Advanced Notice of Proposed Rulemaking (ANPRM) was issued in July 2011, that emphasized two overarching goals:
To achieve the goals, the ANPRM proposed seven regulatory reforms. Approximately 1,100 public comments were received and are being analyzed. The next steps in revising the Common Rule are: publications of a Notice of Proposed Rulemaking (NPRM), analysis of public comments on the NPRM, and promulgation of a Final Rule.
As a related issue, Dr. Hudson noted that the NIH will devote $1 million in bioethics research funding to the development of an evolving, evidence-based approach to ensuring the effectiveness of human subjects protections.
Dr. Shurin updated the Council on NIH leadership appointments and searches:
Dr. Shurin discussed the President's 2013 Budget. The proposed NHLBI budget remains relatively flat overall, with a total increase of 0.02%, or approximately $700 million. However, the Research Project Grant (RPG) line would decrease slightly, due in part to a mandated increase in SBIR/STTR funding (from 2.95% in FY 2012 to 3.05% in FY 2013--part of the SBIR/STTR reauthorization). Despite the RPG funding decrease, a slight increase in numbers of competing RPGs is expected because of variation in grant cycles. The Institute will continue to pay careful attention to where the dollars are going, because although biomedical research costs are increasing, the budget is not. The proposed FY 2013 funding is approximately equivalent to the FY 2000 funding in constant dollars.
The FY 2012 payline remains at the 10th percentile, with Early Stage Investigators receiving an advantage up to the 20th percentile. The Institute is very concerned about the low priority score cutoff, 19, for career development awards, whereas last year grants were funded up to a score of 30. As the fiscal year progresses and more money becomes available, it will be allocated to the RPG and training lines.
The NHLBI must continue to pay attention to protecting its core business, which is research and training. It will do so by:
The Institute believes that fully-funded strategic investments are more likely to thrive than investments receiving across-the-board cuts. The Institute will also continue to support three main scientific priorities: discovery research (including genomics, systems biology, and modeling), regenerative medicine, and translational research.
Dr. Shurin provided an update on the National Center for Advancing Translational Sciences (NCATS). Much effort is focused on the structuring of the new Center. NCATS will facilitate (not duplicate) other translational research activities supported by the NIH, complement efforts of the private sector, and reinforce the NIH's commitment to basic research. The NHLBI will work with NCATS when appropriate.
Dr. Shurin updated the Council on the Global Alliance for Chronic Disease, of which she is now the chair.
Dr. Shurin mentioned that the "Rock Talk" blog from Dr. Sally Rockey, the NIH Deputy Director for Extramural Research, contains valuable information and comments on a variety of issues of concern to the extramural community. She also reported on the primary issues received in response to the Biomedical Workforce Request for Information (RFI), and noted that opportunities to comment may be available soon.
Dr. Arun Chockalingam, Director of the NHLBI Office of Global Health (OGH), described the Office and its strategic plan. The Office, established in April 2010, primarily serves in an integration role, including:
The OGH Strategic Plan consists of five strategies that align with the NHLBI strategic plan:
Dr. Denise Simons-Morton, Director of the NHLBI Division for the Application of Research Discoveries, presented background and the current approach on development of NHLBI-sponsored clinical practice guidelines. NHLBI-sponsored guidelines date to the 1970s, when hypertension guidelines were first reported. The guidelines are published by the Government Printing Office and in journals. NHLBI-sponsored national education programs were integrated with clinical guidelines, and the programs released the guidelines.
The Institute realized that the process of guideline generation needed updating, and sought recommendations on how to do so beginning in June 2005. Additionally, the Institute of Medicine released new recommendations for standards for clinical guidelines in March 2011. The NHLBI is working to follow all of them. The Institute has adopted a new systematic review and guideline development process, and in addition to the National Asthma Education and Prevention Program, it has created two new programs: the now integrated National Program to Reduce Cardiovascular Risk, and the National Blood Disorders Program. Review and clearance of guideline reports now includes NHLBAC review. The Council was informed that it will review the Integrated Cardiovascular Risk Reduction in Children and Adolescents at the current meeting and will review the Sickle Cell Disease draft guidelines in June and the Cardiovascular Risk Reduction in Adults draft guidelines in October.
Dr. Stephen Daniels, Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado; and Chair, Expert Panel on Integrated Guidelines for CV Risk Reduction in Children and Adolescents, discussed the guidelines that were released in December 2011. At the NHLBI National Thought Leaders meeting in 2005, attendees characterized useful guidelines as:
Dr. Daniels mentioned that guidelines should not be considered a final product, but rather a continuously revised one that evolves along with their evidence base. The guidelines panel identified 14 critical questions to address, including a number of risk factors. The recommendations were based on grades by experts of both studies and the body of evidence. A full panel review of recommendations followed a pre-defined consensus process. The guidelines development process resulted in the first evidence-based guidelines with comprehensive systematic review of the literature, and the first integrated pediatric cardiovascular risk reduction guidelines that include all known risk factors, as well as diet and physical activity behaviors.
The guidelines were published in Pediatrics in December 2011. The report can also be found at the website for Pediatric Cardiovascular Risk Reduction Guidelines.
Delegated authorities allow NHLBI staff to perform specific functions without Council involvement, thereby adding flexibility and decreasing the burden on the Council. Dr. Stephen C. Mockrin, Director, Division of Extramural Research Activities, presented the delegated authorities to the Council. The Council was asked to continue the current policy of Delegated Authorities for another year and it agreed.
This portion of the meeting was closed to the public in accordance with the determination that it concerned matters exempt from mandatory disclosure under Sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2).
The session included a discussion of procedures and policies regarding voting and confidentiality of application materials, committee discussions and recommendations. Members absented themselves from the meeting during discussion of and voting on applications from their own institutions, or other applications in which there was a potential conflict of interest, real or apparent. Members were asked to sign a statement to this effect. The Council considered 2,046 applications requesting $2,839,347,174 in total direct costs. The Council recommended 2,046 applications with total direct costs of $2,839,347,174.
The meeting was adjourned at 2:15 p.m. on February 15, 2012.